Exclusive Online Content

R&D Returns Fall to Lowest Level in 9 Years

Projected returns on investment in research and development (R&D) for the top 12 biopharmaceutical companies have fallen to 1.9%, according to a study by Deloitte’s Centre for Health Solutions leveraging revenue forecasts and industry benchmarks generated by GlobalData, a leading data and analytics company.

EXCLUSIVE ONLINE CONTENT